Shik Luen Paul Ip

Array ( [id] => 20414189 [patent_doc_number] => 12497459 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Nucleic acids encoding canine anti-NGF antibodies and methods thereof [patent_app_type] => utility [patent_app_number] => 17/191972 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 29655 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339329 [patent_doc_number] => 12049507 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Felinized anti-NGF antibodies and methods of treating pain [patent_app_type] => utility [patent_app_number] => 17/192368 [patent_app_country] => US [patent_app_date] => 2021-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 34534 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18306387 [patent_doc_number] => 20230110287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => ANTIGEN-BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/905607 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425103 [patent_doc_number] => 12084506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies [patent_app_type] => utility [patent_app_number] => 17/190618 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 34416 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17190618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451554 [patent_doc_number] => 20230192832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB [patent_app_type] => utility [patent_app_number] => 17/905496 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18241966 [patent_doc_number] => 20230074277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => Recombinant calprotectin [patent_app_type] => utility [patent_app_number] => 17/801135 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16964217 [patent_doc_number] => 20210215716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => CIRCULATING SPON-1 (SPONDIN-1) IN THE ASSESSMENT OF ATRIAL FIBRILLATION [patent_app_type] => utility [patent_app_number] => 17/181386 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272187 [patent_doc_number] => 20230093429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3) [patent_app_type] => utility [patent_app_number] => 17/801066 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18444535 [patent_doc_number] => 11680093 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Monoclonal antibodies that specifically bind to matrilin 3 and their use [patent_app_type] => utility [patent_app_number] => 17/177644 [patent_app_country] => US [patent_app_date] => 2021-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 34525 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022331 [patent_doc_number] => 20210246202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => TREATMENTS RELATED TO GH/IGF-1 AXIS INHIBITION [patent_app_type] => utility [patent_app_number] => 17/175393 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336061 [patent_doc_number] => 20220002392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES [patent_app_type] => utility [patent_app_number] => 17/170827 [patent_app_country] => US [patent_app_date] => 2021-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948153 [patent_doc_number] => 20210206844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Anti-FSTL3 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/162776 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18350204 [patent_doc_number] => 20230138315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ANTI-ANGPTL3 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/794213 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17794213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537547 [patent_doc_number] => 20230242645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/792386 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830842 [patent_doc_number] => 20230399367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/040807 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975547 [patent_doc_number] => 11492395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Polynucleotides for preparing ANGPTL 3/8 complexes [patent_app_type] => utility [patent_app_number] => 17/152174 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10483 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977204 [patent_doc_number] => 12344665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody [patent_app_type] => utility [patent_app_number] => 17/144385 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 24022 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806176 [patent_doc_number] => 20210128729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => STABLE AQUEOUS ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/142353 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17142353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822777 [patent_doc_number] => 20210138070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE IMMUNOGLOBULIN CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/135468 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939644 [patent_doc_number] => 20240034783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/788226 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788226 [rel_patent_id] =>[rel_patent_doc_number] =>)